Immunohistochemical basis for FAP as a candidate theranostic target across a broad range of cholangiocarcinoma subtypes
FAP is expressed in the stroma of a high proportion (93%) of primary CCA independent of patient clinical or tumor pathology features. As such, these data provide the tissue basis for systematically evaluating FAP as a theranostic target across a broad range of CCA subtypes.
Authors
- Michael Torbenson (ORCID: https://orcid.org/0000-0002-8334-7725)
- Nguyen H. Tran (ORCID: https://orcid.org/0000-0001-7323-9213)
- Lionel Aurelien Kankeu Fonkoua (ORCID: https://orcid.org/0000-0001-5560-2103)
- Lewis R. Roberts (ORCID: https://orcid.org/0000-0001-7885-8574)
- Laura C. Jorgenson (ORCID: https://orcid.org/0009-0002-1281-1081)
- Rory L. Smoot (ORCID: https://orcid.org/0000-0001-8543-661X)
- Scott M. Thompson (ORCID: https://orcid.org/0000-0001-7853-3278)
- Ajit H. Goenka (ORCID: https://orcid.org/0000-0002-7804-2695)
- Þorvarður R. Hálfdánarson (ORCID: https://orcid.org/0000-0001-8460-1257)
Institutions
- Mayo Clinic in Arizona (US)
Publication Details
- Journal
- Frontiers in Nuclear Medicine
- Published
- 2024-11-27
- DOI
- https://doi.org/10.3389/fnume.2024.1480471
- Citations
- 6
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 1.70